News
Bayer takes lung cancer therapy hope into phase 3

Bayer takes lung cancer therapy hope into phase 3

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to

Debates & Insights

News

Press Releases

Newsletters and Deep Dive
digital magazine

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content